P.K. / Banerjee Preclinical cancer models for translational research and drug development

1. Auflage 2025
ISBN: 978-981-97-5742-8
Verlag: Springer Singapore
Format: PDF
Kopierschutz: 1 - PDF Watermark

E-Book, Englisch, 168 Seiten, eBook

This book provides updated information on certain in vitro and preclinical in vivo cancer models. The topics covered include an update on advancements in the diagnosis, treatment and heterogeneity in certain cancers; the development of preclinical in vitro and xenograft-based in vivo cancer models as well as their validation based on widely accepted biomarkers; modelling of aberrations in bioenergetics in cancers. Also, the importance and latest advances of in silico modeling for the design of new and potent anti-cancer drugs has been reviewed. Cutting-edge and resourceful, this book is valuable for researchers, academicians, and professionals involved in cancer research.
 

Zielgruppe

Research

Autoren/Hrsg.

P.K., Suresh

Banerjee, Arindam

Inhaltsverzeichnis

Preclinical Models for Cancer Research and Development.-Insight on the Current Advancements in the Diagnosis and Treatment of Head and Neck Cancer.- The role of oral cancer heterogeneity in therapies in various cellular and preclinical models.- In-depth analysis of Self-assembled in-vitro spheroidal and organoid systems.- Preclinical in vivo animal xenograft models.- Heterogeneity and biomarkers of therapeutic response and resistance.- Higher Order in vitro Models of dysregulated bioenergetics mechanisms and drug development.- In Silico Strategies for Cancer Model Development and Anticancer Drug Testing.

Über Autor(innen)

Dr. P.K. Suresh is a Professor Higher Academic Grade, Department of Biomedical Sciences, School of Biosciences & Technology, VIT, Vellore. He obtained his doctoral degree from the Department of Environmental Health, College of Medicine, University of Cincinnati, Cincinnati, Ohio, USA. Subsequently, he was a Post-Doctoral Fellow (PDF) at the Department of Pharmacology and Toxicology, University of Texas at Austin, Austin, Texas, USA and at Department of Pharmacology and Toxicology, Rutgers University, Piscataway, New Jersey, USA. His research interests are in the areas of Biomedical Sciences & Biotechnology with a focus on drug development and nanotechnology-based delivery systems as well as on the development and validation of anticancer and wound healing models (2D and 3D). He has been awarded The DST Travel Fellowship that enabled him to travel to Beijing, China for an International conference (presented two papers and chair a session). He has several years of teaching and research experience (about 22 years). He has been a course instructor in several papers including Pharmaceutical Biotechnology, Stem Cell Biology, Immunology & Immuno-technology, Cancer Biology, Ethics & values and Bio-Inspired Design. He has published more than 65 papers in peer-reviewed international journals. He is a member of many national and international scientific societies and organizations importantly, EMSI, ADNAT, BIOCLUES and ISTE.

Dr. Arindam Banerjee is a CEO and Director of LifeSenz Cancer Research Labs Pvt Ltd., Mumbai. Dr. Banerjee is a translational cancer biologist with extensive experience across academia and industry at various international and national levels. His work expertise includes therapy resistance and cancer stem cells, altered metabolism and tumor microenvironment. He has contributed multiple peer reviewed scientific publications, including senior author publication and got accolades at various international scientific meetings. Dr Banerjee is also an expert in advanced and cell modelling based platform development (including 3D models) in cancer therapeutics field. Moreover, he has had extensive experience in scientific project management, academic tutoring and international collaborations. Dr. Banerjee received his PhD in Molecular Medicine from The University of Auckland, New Zealand and subsequent relevant work experience across various international locations such as UK, Singapore, New Zealand and India.